Terminal › Stocks › PSTV

Plus Therapeutics, Inc. (PSTV) Stock

Healthcare · Biotechnology · US

$5.13 +30.74%

Last updated Jun 18, 2026 23:54 UTC

PSTV Key Statistics

Market Cap$12.40M

P/E (TTM)0.00

P/S (TTM)2.38

P/B (TTM)3.99

Revenue (TTM)$5.21M

EPS (TTM)$-30,913.53

Dividend Yield—

ROE (TTM)774.80%

Net Margin-429.43%

Gross Margin91.46%

52W High$8.20

52W Low$2.90

Analyst ViewBuy

Price Target$25.00

Employees21

Volume612,157

About Plus Therapeutics, Inc.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

CEO: Marc H. Hedrick. Company website

See PSTV live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open PSTV in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.